Degron Therapeutics aims to become a global leader in the discovery and development of a new class of targeted protein degradation therapeutics, small molecule molecular glue degrader (MGD) drugs. Degron has assembled a team of world-class executives and scientific leaders, bringing its scientific excellence to the identification and validation of disease targets, particularly those undruggable by conventional small molecule inhibitors, and novel selective MGD compounds to meet unmet medical needs in all therapeutic areas.
Company Details
- Employees
- 16
- Founded
- 2021
- Address
- 3210 Merryfield Row, San Diego,ca 92121,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- San Diego, CA
Degron Therapeutics Questions
Degron Therapeutics's website is http://www.degrontx.com/en/index.php
Degron Therapeutics's LinkedIn profile is https://www.linkedin.com/company/degrontx
Degron Therapeutics has
16 employees.
View email and phone details for 16
employees at Degron Therapeutics.
Degron Therapeutics's industry is
Biotechnology Research
Degron Therapeutics's top competitors are
Monte Rosa Therapeutics,
Triana Biomedicines,
Neomorph, Inc.,
Orionis Biosciences,
Ac Immune,
Bridgene Biosciences, Inc.,
C4 Therapeutics, Inc.,
Seed Therapeutics,
Glubio Therapeutics Inc,
Keros Therapeutics.
Degron Therapeutics's categories are Biotechnology Research
Degron Therapeutics's founding year is 2021
